Recently, human dendritic cells ( DCs ) pulsed with mRNA encoding a broad range of tumor antigens have proven to be potent activators of a primary anti -tumor -specific T -cell response in vitro. The aim of this study was to improve the mRNA pulsing of murine DC. Compared to a standard lipofection protocol and passive pulsing, electroporation was, in our hands, the most efficient method. The optimal conditions to electroporate murine bone marrow -derived DCs with mRNA were determined using enhanced green fluorescent protein and a truncated form of the nerve growth factor receptor. We could obtain high transfection efficiencies around 70 -80% with a mean fluorescence intensity of 100 -200. A maximal expression level was reached 3 hours after electroporation. A clear dose -response effect was seen depending on the amount of mRNA used. Importantly, the electroporation process did not affect the viability nor the allostimulatory capacity or phenotype of the DC. To study the capacity of mRNAelectroporated DCs to present antigen in the context of MHC classes I and II, we made use of chimeric constructs of ovalbumin. The dose -dependent response effect and the duration of presentation were also determined. Together, these results demonstrate that mRNA electroporation is a useful method to generate genetically modified murine DC, which can be used for preclinical studies testing immunotherapeutic approaches.
D
endritic cells (DCs ) are key players in the initiation of immune responses and the activation of naive T cells. 1 Immature DCs are standing guards widely spread in all tissues. Following antigen capture and appropriate ''danger'' signals, they migrate to the T -cell areas of the draining lymphoid organs. During the migration, DCs lose their antigen-capturing and -processing activities while acquiring exceptional presentation and stimulatory capabilities. 2, 3 The colocalization of antigen -loaded DCs and T cells specific for the same antigen is likely the very first step in the induction of an adaptive immune response.
Because of their exceptional potency to activate naive T cells, DCs have been proposed as the basis of cancer vaccines. 4 -7 Different formulations of tumor antigens have been used to load the DC: synthetic peptides, 8, 9 acid -eluted peptides, 10, 11 tumor cell lysates, 12, 13 apoptotic bodies, 14 purified proteins, 15 -17 or nucleic acids. 18 -23 The antigens are then processed and presented on the surface of DCs, leading to activation of T cells.
Because of the limited number of known tumorassociated epitopes and the HLA polymorphism restriction, a vaccination strategy based upon a genetic approach, whereby the whole tumor antigen (containing the maximal epitopic potential ) is processed and presented, has a lot of advantages compared to the more commonly used methods such as peptide loading of DCs. 24 Recently, human DCs pulsed with mRNA encoding a broad range of tumor antigens have proven to be potent activators of a primary anti -tumor -specific T -cell response in vitro. 25 -32 Importantly, a successful vaccine should induce antigen-specific CD4 + as well as CD8 + T cells. The antigen-specific CD4 + T cells are needed for the induction and the maintenance of CD8 + T -cell responses and may directly or indirectly contribute to tumor cell destruction. 33 -38 In this context, genetic modification of DCs through chemokines, cytokines, or membrane -bound immunomodulatory molecules could result in even more potent immunostimulatory cells. 39 -42 Several authors have obtained promising results with human DCs pulsed with either total tumor RNA or in vitrotranscribed RNA encoding different tumor antigens, e.g., CEA, PSA, E6, E7, TERT, and yet undefined antigens derived from cancers of different origin. 25 -28,30 -32 Three pulsing techniques are currently being used, i.e., passive pulsing, lipofection, and electroporation. According to Van Tendeloo et al, 43 electroporation is the most efficient technique to transfect human DCs. As regards genetic modification of mouse DCs with tumor antigens, similar successful results have been reported. 25, 41, 44, 45 To our knowledge, electroporation has not been reported as a pulsing technique for mouse DCs.
In this study, we investigated the possibility to genetically modify mouse bone marrow -derived DCs by electroporation with in vitro -transcribed mRNA. The optimal electroporation conditions were determined using mRNA coding for the reporter gene eGFP 46 and the truncated NGF -R. 47 To analyze the antigen presentation by the modified DCs, an mRNA was used for coding of a truncated form of the model antigen ovalbumin (tOVA ), 19 modified by the addition of ubiquitin, an intracellular degradation signal, 48 -50 or by an endolysosomal targeting signal derived from the invariant chain. 51 -55 We demonstrate that DCs can be efficiently transfected with mRNA using electroporation and that the chimeric OVA constructs were efficiently processed and targeted to both the MHC class I and/ or class II processing pathways. We also show that mRNA -electroporated DCs are far superior in the antigen presentation assay compared to mRNA -pulsed DCs.
Materials and methods
Mice, cell lines, and reagents C57BL /6 (H -2 b ) female mice, 6-8 weeks old, were obtained from Harlan (Horst, the Netherlands ). Animals were maintained and treated according to the Institutional Guidelines.
The tumor cell lines used were EL4 lymphoma ( C57BL / 6, H -2 b ) and E.G7 -OVA (EL4 cells transfected with chicken OVA cDNA; ATCC, Rockville, MD ). EL4 cells were maintained in DMEM ( Invitrogen -Life Technologies, Merelbeke, Belgium ) supplemented with 5% heatinactivated FCS, 2 mM glutamine, 50 M 2-ME, 100 U/mL penicillin, and 100 g/ mL streptomycin. E.G7 -OVA cells were grown in the same medium containing 400 g/mL G418 (Eurobiochem, Bierges, Belgium ). The T -cell hybridoma RF33.70, which recognizes an H -2 -K b -restricted OVA peptide ( aa 257-264 ), and the T -cell hybridoma MF2.2D9, which recognizes an H -2-I-A b -binding epitope located within aa 265 -280 of the OVA protein sequence, were kindly provided by Dr KL Rock (Boston, MA ). These cell lines secrete IL -2 upon recognition of the OVA epitopes in the context of the corresponding restriction elements. The amount of IL -2 was determined using the indicator cell line CTLL -2. All cell lines used were free of mycoplasma.
Generation of bone marrow -derived DC
Bone marrow -derived DCs were generated following the protocol described by Lutz et al. 56 Briefly, bone marrow cells were isolated from the hind limbs and treated with red blood cell lysis buffer. The cells were plated in a 10 -cm bacteriological Petri dish (Falcon -Becton Dickinson, Erembodegem, Belgium ) at 2Â10 6 cells in 10 mL of complete medium ( DMEM supplemented with 5% heat -inactivated FCS, 2 mM glutamine, 50 M 2 -ME, 100 U /mL penicillin, 100 g/mL streptomycin, and 20 ng /mL rmo GM -CSF ). On day 3 of culture, 10 mL of culture medium containing 20 ng /mL rmo GM -CSF was added. On day 5, 50% of the medium was refreshed with culture medium containing 20 ng /mL rmo GM -CSF. On day 7, cells were used for mRNA electroporation and according to the experimental set -up DCs were further matured with LPS derived from Escherichia coli serotype O55:B5 ( Sigma -Aldrich, Bornem, Belgium ) at a concentration of 0.1 g /mL.
Plasmids and in vitro transcription of mRNA
The vector pGEM -4Z 5 0 UT -eGFP -3 0 UT -A64 was kindly provided by Dr E Gilboa. This plasmid contains a 741-bp eGFP fragment from peGFP -N1 ( Clontech, Westburg, Leusden, the Netherlands ) flanked by the 5 0 and 3 0 UTRs of Xenopus laevis b-globin and 64 A -T bp. Transcription is controlled by a bacteriophage T7 promoter. SpeI and NotI sites are present at the 3 0 end of the A64 stretch to allow linearization of the plasmid before in vitro transcription. The truncated human NGF -R ( extracellular and transmembrane fragment ) was amplified from the plasmid ptNGFR kindly provided by Dr C Traversari (Instituto Scientifico HSRaffaele, Milan, Italy ). The primers used for polymerase chain reaction ( PCR ) were: 5 0 -CCCTCATGAGGGCAGGTGC-CACCG -3 0 and 5 0 -GGGAGATCTCTAGAGGATCCCCC-TCTTCC -3 0 . During the PCR, a 5 0 BspHI site spanning the start codon and a stop codon and a BglII site at the 3 0 end were inserted. The eGFP gene was excised from pGEM -5 0 UT -eGFP -3 0 UT -A64 with NcoI and BamHI and replaced with the BspHI -BglII fragment containing the truncated NGF -R gene.
The gene fragment coding for the 80 amino -terminal residues of the murine invariant chain was amplified from pcDNA1moIi80ova, kindly provided by Dr K Frauwirth ( University of California, Berkeley, CA ). Primers used in PCR were:5 0 -TTTCCATGGATGACCAGCGCGAC -3 0 and 5 0 -TTTGGATCCGGAAGCTTCATGCGCAGGTT -3 0 . This PCR adds a NcoI site spanning the start codon and a BamHI site at the 3 0 end. Ubiquitin was amplified from C57BL /6 mouse cDNA using the following primers: 5 0 -GGGCCAT-GGAAATCTTCGTGAAGACCCTG -3 0 and 5 0 -ACACGG-ATCCCCACCGCGCAGACGCAG -3 0 . This PCR adds a NcoI site and a BamHI site at the 5 0 and 3 0 ends of the cDNA. The eGFP gene was excised with NcoI and BamHI and replaced by a NcoI-BamHI fragment containing the amino -terminal part of the mouse invariant chain ( pGEMmoIi80 ). The same strategy was used for the replacement of eGFP by ubiquitin ( pGEM -Ubi ). The cDNA coding for OVA was truncated at its 5 0 end in order to remove the ER translocation signal. The tOVA protein is not secreted and mimics a tumor -associated antigen expressed in the cytosol. A BamHI fragment that contains tOVA was ligated into BamHI -linearized pGEM -moIi80 and pGEM -Ubi vectors, resulting in pGEM -moIi80.tOVA and pGEM -Ubi.tOVA.
For in vitro transcription, the plasmids were linearized with either SpeI ( pGEM -eGFP ) or NotI ( pGEM -moIi80.-tOVA and pGEM -Ubi.tOVA ). The linearized plasmids were used as template for the mMessage mMachine in vitro transcription system ( Ambion, Austin, TX ). The concentration and quality of the in vitro -transcribed mRNA were assessed by spectrophotometry and agarose gel electrophoresis.
Cancer Gene Therapy Lipofection of DCs was performed following the manufacturer's instructions with minor modifications: 20 g of mRNA diluted in 250 L of Opti -MEM was mixed with the cationic lipid DMRIE -C (Invitrogen -Life Technologies ), also diluted in 250 L of Opti -MEM, at a lipid -to -mRNA ratio of 4:1. After incubation for 5 -15 minutes at room temperature in order to allow mRNA -lipid complexation, lipoplexes were added to 2 mL of DCs suspension in Opti -MEM ( 5Â10 5 cells/mL ) and incubated for 4 hours at 378C. Alternatively, 2 mL of DCs suspension was passively pulsed with 20 g of mRNA in the absence of DMRIE -C for 4 hours at 378C. After lipofection or passive pulsing, the cells were further cultured in fresh complete medium at 378C in a humidified atmosphere supplemented with 7% CO 2 .
Peptide loading of DC
At day 7, DCs were harvested, washed twice in PBS, and collected in a 15-mL polystyrene tube in Opti -MEM medium at a concentration of 4Â10 
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Flow cytometric analysis
The phenotypic profile of the BM -derived DCs, the expression of the truncated NGF -R, and the presentation of OVA in the context of MHC class I were analyzed by flow cytometry. The monoclonal antibodies anti -CD11c ( N418 ), anti -B7.1 (16-10A1 ), 57 anti -B7.2 ( GL -1), anti -CD40 ( FGK45 ), 58 anti -I-A /I-E (B21 -2), anti -NGF -R (20.4 ), and anti -K b -SIINFEKL (25 -D1.16 ) 59 were affinity -purified from tissue culture supernatants and conjugated to biotin. DCs were incubated for 30 minutes with the biotinylated detection mAb and, after washing, stained with Streptavidin -Cy -Chrome (BD PharMingen, Heidelberg, Germany ). All stainings were performed on ice in PBS containing 1% BSA, 0.02% sodium azide, and 10% 2.4G2 mAb supernatant to reduce nonspecific binding through the FcgRII ( CD32 ). Stained cells were fixed in 1% paraformaldehyde in PBS and analyzed on a FACS Calibur flow cytometer using Cell Quest software (Becton and Dickinson Immunocytometry Systems, San Jose, CA ). All stainings were compared to irrelevant isotype control stainings.
Allogeneic T -cell proliferation
The ability of electroporated DCs to stimulate resting T cells was assessed by an allo -mixed leukocyte reaction ( MLR ).
Day 7 C57BL /6 bone marrow -derived DCs were either nontransfected, mock -electroporated, or electroporated with Ii80.tOVA mRNA as described in Materials and Methods and matured with LPS for 4 hours. The cells were harvested at day 8, mitomycin C -treated, and plated at graded concentrations in the presence of 2Â10 5 BALB /c nylon wool purified T cells in 200 L of DMEM with supplements. After 3 days of incubation at 378C, 5% CO 2 , the cells were pulsed overnight with 1 Ci/ well [ 3 H ]thymidine. Incorporation of [ 3 H ]thymidine was measured using a b-scintillation counter (Microbeta -Wallac, Turku, Finland).
Antigen presentation assay
To determine whether the electroporated DCs presented OVA -derived peptides in the context of either MHC class I or II molecules, OVA -specific T -cell hybridoma cells (5Â10 
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Results
Electroporation of bone marrow -derived DCs with in vitro -transcribed mRNA is a highly efficient and nontoxic transfection method
In order to improve the loading of DCs with tumor antigenencoding mRNA, we investigated the transfection efficacy of electroporation of murine bone marrow -derived DCs with in vitro -transcribed mRNA. We used eGFP -encoding mRNA as a tool to test different parameters. Flow cytometric analysis was used to monitor the transfection efficiency and the level and kinetics of the reporter gene expression.
To address the feasibility of the transfection of murine DCs, we used the same electrical settings as recently described for the successful electroporation of human monocyte -derived DCs. 43 Flow cytometric analysis and viability assessment were performed at different time points after electroporation. Figure 1 shows a representative flow cytometric analysis of DCs 24 hours after electroporation with 20 g of eGFP -encoding mRNA. Twenty-four hours after transfection, 70% ( mean of seven experiments ) of the DCs, gated on their forward and sideward scatter characteristics, expressed eGFP with an MFI of 100. Optimal transfection efficiency was obtained when DCs were used on day 7 of culture (data not shown). Figure 2 shows the percentage of positive cells and the fluorescence intensity at different intervals after electroporation. A maximal transfection efficiency was detected already 3 hours after electroporation and sustained for 24 hours. The expression level reached a maximum 3 hours after electroporation and then decreased slowly. The efficacy of the electroporation process ( i.e., the percentage of eGFP -positive cells ) was within the same range when 20, 10, or 5 g of mRNA was used. The expression level, however, decreased when lower amounts of mRNA were used (Fig 3 ) . The electroporation procedure had no effect on the viability of the cells.
To confirm the results obtained with eGFP mRNA, of which only a few molecules are needed to render the cells fluorescent, we repeated the experiments with mRNA encoding a membrane -bound molecule, namely, a truncated form of NGF -R. Similar results were obtained ( Fig 2) .
In summary, electroporation of murine DCs with in vitrotranscribed mRNA is a very efficient and a nontoxic method for transient genetic modification of these cells.
Electroporation is much more efficient to introduce mRNA into DCs than passive pulsing and lipofection
To evaluate the efficacy of various mRNA pulsing methods, presentation of the OVA transgene by C57BL /6 DC, in the Figure 4 , presentation of OVA, both in the context of MHC classes I and II, was negligible after passive pulsing and very low after lipofection. The presentation of OVA by electroporated DCs was 5 -fold higher than by lipofected DCs. The effect of the transfection method on the viability of the DCs was assessed after 24 hours by PI staining and FACS analysis. Around 6% of cell death occurred after passive pulsing, mock electroporation, and Ii80.tOVA mRNA electroporation, whereas 23% cell death occurred after lipofection of DCs (data not shown).
In summary, electroporation of DCs proved a much more efficient method to introduce mRNA into DCs than passive pulsing and lipofection.
Electroporation does not hamper the maturation potential nor the allostimulatory capacity
The effect of the electroporation upon the maturation status of the DCs, their capacity to further mature upon LPS exposure, and, accordingly, their stimulatory capacity to induce an allo -mixed leukocyte reaction were investigated. First, immature DCs and LPS -treated DCs that were either nontransfected, mock -electroporated, or electroporated with eGFP mRNA were analyzed by FACS for the expression of several surface markers (Fig 5 ) . The expression of CD11c, a DC -specific marker, was around 80% on day 8 of culture and comparable for all DCs culture conditions. Importantly, a clear up -regulation of the DCs maturation markers, CD86 and CD40, was detected upon a 24 -hour LPS stimulation of either nontransfected and mock -electroporated DCs as well as of DCs electroporated with eGFP mRNA. These data demonstrate that electroporation in the absence or presence of mRNA does not inhibit the maturation capacity of the 
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DCs upon LPS stimulation. Moreover, the electroporation itself, in the absence or presence of mRNA, did not induce maturation of the DC. Further, we determined the optimal point of time to start the maturation process. A slightly better maturation was observed when LPS was added immediately after transfection compared to the addition 24 hours before or after electroporation ( data not shown ). We also examined the incubation time necessary to induce full maturation of DCs. FACS analysis for maturation markers showed that a 4 -hour incubation with 0.1 g /mL LPS was sufficient (two separate experiments) to induce maximal maturation. Secondly, an allo -MLR was performed to investigate whether the electroporation had an effect upon the stimulatory activity of bone marrow DC. C57BL /6 spleen cells and 4 -hour LPS -treated C57BL /6 DC, which were either nontransfected, mock -, or Ii80.tOVA -electroporated, were cocultured with BALB /c T lymphocytes at a T:DCs ratio of 40:1 ( Fig 6) . The proliferation was measured by [ 3 H ]thymidine incorporation after 3 days of culture. No significant difference was detected between the different DCs populations in stimulating the allogeneic T cells (three separate experiments).
In conclusion, the electroporation process neither inhibits nor induces maturation of DCs, as illustrated by the findings that electroporated DCs are equally well matured upon exposure to LPS, and have the same phenotypic characteristics and the same allostimulatory capacity as nontransfected DCs treated in a similar way. Genetic modification of DCs by mRNA electroporation does not hamper the immunostimulatory capacity of DCs and thus could be suitable for immunotherapeutic purposes.
Electroporated DCs process and present OVA peptides both in the context of MHC classes I and II Considering the use of mRNA -electroporated DCs as a vaccine modality in cancer immunotherapy, it is of great importance that the antigen is processed and efficiently presented in the context of MHC class I as well as of MHC class II to allow induction of CD4 + T -cell help for activation and maintenance of tumor-specific CD8 + T cells. In this context, we constructed two different OVA vectors, namely, pGEM -Ubi.tOVA and pGEM -Ii80.tOVA. As seen in Figure 7 , the Ubi.tOVA construct, which is degraded in the cytosol by the proteasome, gave rise to MHC class I presentation only, whereas the Ii80.tOVA construct, which targets the encoded protein towards the endolysosomal pathway, ensures both MHC classes I and II presentation. Accordingly, we decided to use the Ii80.tOVA construct in further experiments. Analogous to the experiments wherein the transfection efficiency and the expression level (MFI ) of eGFP in function of time were determined, the duration of the OVA presentation in MHC classes I and II after electroporation was investigated. We also determined whether the amount of mRNA used for electroporation had an effect on the presentation level of the DCs. Therefore, DCs were transfected with increasing amounts of Ii80.tOVA mRNA and a presentation assay was performed 24, 48, and 72 hours after electroporation using either the RF33.70 or the MF2.2D9 TT hybridoma cells. As shown in Figure 8 , the optimal presentation of both MHC class I-and MHC class IIrestricted OVA epitopes occurred 24 hours after transfection and then decreased gradually. We observed a clear dosedependent response effect for the presentation of OVA in the context of MHC class I as well as in the context of MHC class II. In Figure 9 , the kinetics of presentation by Ii80.tOVA b -SIINFEKL complex gradually decreased in time and a clear dose -related response effect was seen. These observations were both in correlation with the presentation assay. Important to notice is that the expression level of the K b -SIINFEKL complex by Ii80.tOVA mRNA -electroporated DCs was very low compared to peptide -loaded DCs, as shown in Figure 11 . This low FACS staining contrasts to the highly efficient activation of the OVA -K b -restricted hybridoma.
In conclusion, LPS -matured DCs electroporated with the Ii80.tOVA construct efficiently present OVA peptides in the context of both MHC classes I and II, with an optimal presentation level 24 hours after transfection.
Discussion
Nowadays, many cancer patients cannot benefit from recently developed immunotherapies based upon the use of tumor antigen -loaded DC. Often, the available tumor tissue is too small to prepare tumor lysates or apoptotic bodies and to extract tumor proteins or peptides, which can then be used for DCs loading. 60 Due to the haplotype restriction, the use of peptides derived from tumor-associated antigens is also limited.
Because of the potential broader applicability, we favor the use of genetically modified DCs. 19 Important advantages related to this approach are the independence of the patient's haplotype, 60 -63 the potency to present several potentially immunogenic epitopes derived from the endogenously expressed full -length tumor protein, and the possibility to modify the tumor-encoding cDNA by adding degradation or targeting signals to promote the processing and presentation of tumor antigen -derived epitopes. Many different methods have been developed to introduce genetic information into DCs. Disadvantages encountered after viral transduction of DCs are toxicity, impaired APC function, and expression of strong immunogenic viral antigens limiting multiple immunizations. 23,61,63 -65 In addition, the use of viral particles as a vehicle for tumor antigen delivery is very timeconsuming due to the laborious production, purification, and titration steps. Boczkowski et al 45 have pioneered the use of RNA to genetically modify DCs. Tumor -derived or in vitro -transcribed mRNA as a vehicle for the delivery of tumor antigens has many advantages over the more commonly used methods. 29 The benefits of using mRNA rather than DNA comprise its safety and the fact that entry of mRNA into the cytoplasm is sufficient for transient translation, whereas DNA must enter the nucleus to be transcribed and can integrate into the host genome. 66 Besides, nonviral DNA transfection methods are inefficient, particularly in nondividing cells. 43, 67 Another important issue to note is that tumor mRNA can be isolated from a small tumor burden and can serve as a reliable source of tumor antigen. 25 Moreover, the RNA can be amplified in vitro and genetically modified or enriched by subtractive hybridization. 25, 45, 68 The aim of this study was to increase the expression and presentation level of the tumor antigen after mRNA pulsing of murine bone marrow -derived DCs. Electroporation, using the same electrical settings as recently described by Van Tendeloo et al, proved to be a much more efficient method than passive pulsing and lipofection when we compared the presentation of OVA peptides by the mRNAmodified DCs. It should be mentioned that Gilboa et al have been able to obtain impressive cellular immune responses in vitro and in vivo against various human and mouse tumor antigens using either lipofected or passively pulsed DCs, although these investigators rarely showed the transfection efficiency of their method. In our hands, the passive pulsing of DCs was much less efficient compared to electroporation as demonstrated by FACS analysis and antigen presentation assays. This might be due to the amount or concentration of mRNA or the cell density used in our experiments. We have not investigated these parameters in detail nor optimized the passive pulsing approach. We further optimized the conditions to electroporate murine bone marrow -derived DCs. Using eGFP as a reporter gene, we obtained transfection efficiencies of 70 -80% when DCs were electroporated on day 7 of culture with 20 g of eGFP mRNA. Similar results were obtained when a truncated form of NGF -R was used as a reporter gene. Importantly, the electroporation process did not affect the viability of the DC, their immunophenotype, their capacity to respond to a maturation stimulus, nor their capacity to activate allogeneic T cells in a mixed leukocyte reaction assay. The optimal transfection efficiency, with the highest mean fluorescent intensity, was detected 3 hours after electroporation and then decreased gradually. The efficacy of the electroporation process was within the same range when 2, 10, or 5 g of mRNA was used, whereas the expression level decreased when lower amounts of mRNA were used. In this way, it is possible to influence the expression level of the transgene in the mRNA -electroporated DCs. The avidity of the T -cell response induced by immunization with DCs electroporated with different amounts of mRNA remains to be investigated. Theoretically, it is expected that the avidity of the T -cell response will increase when a lower amount of antigen is Cancer Gene Therapy Electroporation of murine dendritic cells S Van Meirvenne et al presented. 69 -71 This is important because T cells with high avidity are more potent in the recognition and eventual killing of tumor cells in vivo.
The OVA antigen was chosen as tumor model antigen to study the presentation of antigenic peptides by mRNAelectroporated murine bone marrow -derived DCs. A truncated form of OVA (tOVA ) was used to mimic a cytosolic expressed tumor antigen. After modification of the tOVA -encoding cDNA with ubiquitin to enhance the proteasome -mediated degradation, electroporated DCs presented OVA peptides only in the context of MHC class I. Modification with the endosomal targeting sequence derived from the invariant chain resulted in presentation of OVA peptides both in the context of MHC classes I and II. Because of the importance of CD4 + T -cell help for the induction of an effective and long -lasting memory CTL response in vivo, 33 -38 we decided to use Ii80.tOVA mRNA in further experiments. Analogous to the results with eGFP, the optimal presentation of both MHC class I-and MHC class II -restricted OVA epitopes occurred 4 hours after transfection and then decreased gradually. We also could observe a clear dose -dependent response effect for the presentation of both peptides. When, in a TT hybridoma assay, the level of OVA presentation in MHC class I or II by electroporated DCs was compared to peptide -loaded DCs, no major differences were observed. Until 48 hours, mRNA -electroporated DCs and DCs loaded with 10 M and 1 M SIINFEKL peptide presented the MHC class I epitope equally well. The expression of the MHC class IIpeptide complex was less stable both for mRNA -electroporated and peptide -loaded DCs compared to the MHC class I-peptide complex. At all times, DCs loaded with 10 M OVA 265 -280 -I-A b peptide were remarkably better stimulators of the MF2.2D9 than mRNA -electroporated DCs. To determine the number of cells presenting the K b -SIINFEKL complex and the expression niveau on a single cell level, a FACS staining with the mAb 25-D1.26 was performed. When day 7 DCs were electroporated with 20 g of Ii80.tOVA mRNA, only 20% of the cells stained positive. Besides this, a clear dose -response effect and a gradual decrease in time of the K b -SIINFEKL complex with an optimum 24 hours after electroporation were observed. We noticed that the transfection efficiency, determined in this way, was much lower compared to the transfection efficiency estimated after eGFP or truncated NGF -R mRNA electroporation. We assume that the reason for this discrepancy might be due to the limited sensitivity of this assay. An observation that supports this hypothesis is the fact that the K b -positive cell lines transfected with an OVAencoding vector, E.G7 -OVA, and MO4 cells 72 could not be stained with the mAb 25-D1. 26 . As a control, DCs loaded with increasing concentrations of SIINFEKL peptide were included. A dose -dependent response effect was observed and a clear positive signal was still detected for DCs loaded with 0.1 M SIINFEKL peptide. It should be noted that the concentration of peptide needed for detection of K b -SIINFEKL complexes by the 25-D1.26 mAb is much higher than the concentration that is required for the activation of the RF33.70 TT hybridoma cells. 73 For the latter, additional interactions between DCs and T cells such as costimulatory and adhesion molecules or cytokines can support stimulation.
We can conclude that the use of mRNA -electroporated DCs is a reliable and safe strategy and holds promise for immunotherapy against cancer. We are now optimizing and evaluating the use of human clinical -grade DCs electroporated with different tumor-associated antigens to start a clinical trial.
